ICUI logo

ICU MEDICAL INC

ICUINASDAQ
πŸ† #1411 by market capEarnings Nov 5US Equity
$169.20β–² $2.83 (+1.70%)
Latest quote
πŸ””
Track ICUI
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 1.7%
7dβ–² 0.5%
14dβ–² 1.1%
30dβ–² 3.5%
ytdβ–² 18.8%
1yβ–² 43.9%
🏦Market Cap
$4.23B
Small Cap
πŸ“ˆRevenue Growth (YoY)
-9.0%
Declining
πŸ“ŠGross Margin
39.1%
Healthy
πŸ’΅FCF Margin
6.7%
Moderate
βš–οΈP/S Ratio
1.9x
Cheap
Otter Score
68
Fair

Trading Snapshot

Day Range
$167.28 – $169.55
52-Week Range
$113.37 – $192.85
Volume (shares)
9,026
Avg Volume (shares)
β€”
Shares Outstanding
25.0M
Next Earnings
2026-11-05

Fundamentals Snapshot

Annual Revenue
β€”
Last Q Revenue
β€”
P/E Ratio
136.5
P/S Ratio
1.9x
EPS (TTM)
$1.18
Dividend Yield
β€”
Dilution (1yr)
+0.8%
ICUI logo

ICU MEDICAL INC

ICUI
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$2.2Bβ–Ό βˆ’6.4% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
36.8%β–² +6.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$107Mβ–² +148.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$92Mβ–Ό βˆ’26.4% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
24.7Mβ–² +0.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$1.1Bβ–² +$249M YoY
StockOtter Β· stockotter.space

About ICU MEDICAL INC

ICU Medical, Inc., operating globally through its subsidiaries, is a medical technology firm that specializes in the development, manufacture, and sale of devices for both infusion therapy and critical care. Their extensive product line for infusion therapy encompasses: Needlefree Connectors: Such as the MicroClave, MicroClave Clear, and NanoClave brands. Catheter Maintenance & Disinfection: Including Neutron patency devices and SwabCap/SwabTip disinfecting caps. Hemodialysis Solutions: Like Tego connectors and ClearGuard HD antimicrobial caps. Hazardous Drug Handling: With closed system transfer devices (ChemoClave, ChemoLock) and the Diana compounding system for safe preparation. They also provide a comprehensive range of intravenous (IV) solutions, diluents, and irrigation fluids, available in diverse packaging options like flexible containers and pour bottles. These include common formulations such as sodium chloride, dextrose, balanced electrolytes, lactated ringer's, mannitol, and sterile water, alongside specialized irrigation solutions like acetic acid and glycine. In medication management, ICU Medical offers sophisticated infusion pumps, including the Plum 360 and LifeCare PCA brands. Its advanced ICU Medical MedNet software enhances medication safety by integrating smart pumps with hospital electronic health records (EHRs), asset tracking, and alarm notification platforms. Accompanying professional services are also provided. For critical care environments, their portfolio features: Hemodynamic Monitoring: Systems like Cogent 2-in-1 and CardioFlo. Cardiac Output & Oximetry: TDQ, OptiQ, and TriOx catheters. Blood Pressure Transducers: Such as Transpac. Blood Sampling Systems: Including the SafeSet closed blood sampling and conservation systems. The company distributes its products to a wide spectrum of healthcare providers, including acute care hospitals, wholesalers, ambulatory clinics, and various alternate site facilities such as outpatient clinics, home healthcare services, and long-term care centers. Established in 1984, ICU Medical maintains its headquarters in San Clemente, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Fair
68/100

Analyst Ratings

β“˜
Consensus
Buy
13 analysts
Strong Buy5
Buy7
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.